APA

Narui K., Ishikawa T., Shimizu D., Yamada A., Tanabe M., Sasaki T., Oba M. S., Morita S., Nawata S., Kida K., Mogaki M., Doi T., Tsugawa K., Ogata H., Ota T., Kosaka Y., Sengoku N., Kuranami M., Niikura N., Saito Y., Suzuki Y., Suto A., Arioka H., Chishima T., Ichikawa Y., Endo I. & Tokuda Y. (20200204). Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. : Breast (Edinburgh, Scotland).

Chicago

Narui Kazutaka, Ishikawa Takashi, Shimizu Daisuke, Yamada Akimitsu, Tanabe Mikiko, Sasaki Takeshi, Oba Mari S, Morita Satoshi, Nawata Shuichi, Kida Kumiko, Mogaki Masatoshi, Doi Takako, Tsugawa Koichiro, Ogata Haruki, Ota Tomohiko, Kosaka Yoshimasa, Sengoku Norihiko, Kuranami Masaru, Niikura Naoki, Saito Yuki, Suzuki Yasuhiro, Suto Akihiko, Arioka Hitoshi, Chishima Takashi, Ichikawa Yasushi, Endo Itaru and Tokuda Yutaka. 20200204. Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. : Breast (Edinburgh, Scotland).

Harvard

Narui K., Ishikawa T., Shimizu D., Yamada A., Tanabe M., Sasaki T., Oba M. S., Morita S., Nawata S., Kida K., Mogaki M., Doi T., Tsugawa K., Ogata H., Ota T., Kosaka Y., Sengoku N., Kuranami M., Niikura N., Saito Y., Suzuki Y., Suto A., Arioka H., Chishima T., Ichikawa Y., Endo I. and Tokuda Y. (20200204). Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. : Breast (Edinburgh, Scotland).

MLA

Narui Kazutaka, Ishikawa Takashi, Shimizu Daisuke, Yamada Akimitsu, Tanabe Mikiko, Sasaki Takeshi, Oba Mari S, Morita Satoshi, Nawata Shuichi, Kida Kumiko, Mogaki Masatoshi, Doi Takako, Tsugawa Koichiro, Ogata Haruki, Ota Tomohiko, Kosaka Yoshimasa, Sengoku Norihiko, Kuranami Masaru, Niikura Naoki, Saito Yuki, Suzuki Yasuhiro, Suto Akihiko, Arioka Hitoshi, Chishima Takashi, Ichikawa Yasushi, Endo Itaru and Tokuda Yutaka. Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. : Breast (Edinburgh, Scotland). 20200204.